{"article_title": "Biogen cuts 2015 profit outlook as key MS drug sales slow", "article_keywords": ["outlook", "slow", "tecfidera", "ms", "profit", "adjusted", "share", "sales", "drug", "research", "surveyed", "earnings", "key", "cuts", "2015", "biogen", "investment", "zacks"], "article_url": "http://www.washingtontimes.com/news/2015/jul/24/biogen-cuts-2015-profit-outlook-as-key-ms-drug-sal/", "article_text": "CAMBRIDGE, Mass. (AP) - Biogen cut its full-year adjusted profit forecast Friday as sales of one of its multiple sclerosis drugs, Tecfidera, slow down.\n\nShares dropped almost 17 percent in morning trading Friday.\n\nThe biotechnology company now expects 2015 adjusted earnings in the range of $15.50 to $15.95 per share. Its prior guidance was for adjusted earnings between $16.60 and $17 per share.\n\nAnalysts surveyed by FactSet predict earnings of $16.63 per share.\n\nIn the second quarter, the Cambridge, Massachusetts-based company posted revenue of $2.59 billion, which missed Wall Street forecasts. Eighteen analysts surveyed by Zacks Investment Research expected $2.71 billion.\n\nCEO George Scangos said in a written statement that the multiple sclerosis drug Tecfidera is \u201cexperiencing moderated patient growth following rapid initial uptake.\u201d\n\nIn the first quarter, Tecfidera sales climbed 63 percent from the prior-year period. The drug experienced 26 percent sales growth in the second quarter.\n\nFor the three months ended June 30, Biogen Inc. earned $927.3 million, or $3.93 per share. That compares with $714.5 million, or $3.01 per share, a year earlier. Earnings, adjusted for one-time gains and costs, were $4.22 per share.\n\nThe results topped Wall Street expectations. The average estimate of 19 analysts surveyed by Zacks Investment Research was for earnings of $4.10 per share.\n\nBut the reduced forecast weighed on the stock. Biogen\u2019s shares declined $64.47, or 16.8 percent, to $320.58 in morning trading.\n\n_____\n\nElements of this story were generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BIIB at http://www.zacks.com/ap/BIIB\n\n_____\n\nKeywords: Biogen Idec, Earnings Report", "article_metadata": {"description": "Biogen cut its full-year adjusted profit forecast Friday as sales of one of its multiple sclerosis drugs, Tecfidera, slow down.", "author": "The Washington Times http://www.washingtontimes.com", "og": {"url": "http://www.washingtontimes.com/news/2015/jul/24/biogen-cuts-2015-profit-outlook-as-key-ms-drug-sal/", "site_name": "The Washingtion Times", "type": "article", "description": "Biogen cut its full-year adjusted profit forecast Friday as sales of one of its multiple sclerosis drugs, Tecfidera, slow down.", "title": "Biogen cuts 2015 profit outlook as key MS drug sales slow"}, "twitter": {"description": "Biogen cut its full-year adjusted profit forecast Friday as sales of one of its multiple sclerosis drugs, Tecfidera, slow down.", "site": "@washtimes", "card": "summary", "title": "Biogen cuts 2015 profit outlook as key MS drug sales slow"}, "bitly-verification": "d180fd45f70d", "format-detection": "telephone=no", "msvalidate.01": "5B44585918D69318CA2120B5FA20D85C", "serverf": "web1", "viewport": "width=device-width, initial-scale=1, user-scalable=yes"}, "_id": "\"57477af46914bd0286fdaaa9\"", "article_summary": "_____Elements of this story were generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research.\n(AP) - Biogen cut its full-year adjusted profit forecast Friday as sales of one of its multiple sclerosis drugs, Tecfidera, slow down.\nThe biotechnology company now expects 2015 adjusted earnings in the range of $15.50 to $15.95 per share.\nEighteen analysts surveyed by Zacks Investment Research expected $2.71 billion.\nThe average estimate of 19 analysts surveyed by Zacks Investment Research was for earnings of $4.10 per share."}